3 potentially overvalued FTSE stocks I’d still consider buying on a dip

Some recent stock market successes for UK companies have resulted in over-inflated stock prices. I look at three worth watching in 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While worldwide worries have prevented many stocks from thriving in 2019, a select few have defied expectations and done extremely well. Positive sentiment drives buyers to these stocks, but it can also result in them becoming overvalued, when they become too expensive for their own good.

I think this is the case for several such successes in recent months, but there are still a few I’d take my chances with, particularly if the share price drops.

From the FTSE 100, I’d choose global pharmaceutical giant Astrazeneca (LSE:AZN), while from the FTSE 250, I’d choose Future (LSE:FUTR), an international media group and digital publisher, and JD Sports Fashion, the sports retailer.

Health for wealth

Astrazeneca has had an exceptionally good year. Its share price has risen over 27% since January.  This is thanks to several positive developments in its drug research and commercialisation.

It specialises in the treatment of diseases in the areas of oncology, cardiovascular, renal and metabolism, and respiratory.

November alone was impressive. Its drug Imfinzi was granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer, an aggressive, fast-growing form of lung cancer. Calquence, a leukaemia drug, was approved in the US for adult patients, Qtrilmet was approved in the EU for the treatment of type-2 diabetes, and the FDA accepted a New Drug Application and granted Priority Review for Selumetinib, as a potential new medicine for paediatric patients with NF1, a rare and incurable genetic condition.

This pharma favourite has a trailing price-to-earnings ratio (P/E) of 47 and its dividend yield is 2.9%. Earnings per share are £1.31 and its debt ratio is 68%.

Future returns

Customer loyalty has contributed to record revenue growth for Future and according to the London Stock Exchange, its e-commerce clicks soared 44% year-on-year following Black Friday 2019.

This publishing giant’s top online properties include technology sites TechRadar, GamesRadar, and Tom’s Guide. Leading products advertised and sold through these sites on Black Friday included Google’s Pixel 4 smartphone, and the Sony Playstation VR, as well as subscriptions to streaming services such as Hulu and Disney+.

The relevance and trusted nature of these sites give consumers the confidence to shop online as the sites offer expert buying advice across consumer categories such as tech, games, music, homes, and more.

Future has recently announced two major acquisitions; a £140m acquisition of TI Media, a UK-based print-let consumer magazine and digital publisher with brands such as Marie Claire and World Soccer. This preceded the £23.5m acquisition of Barcroft Studios, creator of digital video and television content.

Future has an astronomical trailing P/E of 138. Its dividend yield is a very low 0.14% but the cover is more than 10 times. Earnings per share are 9p and its debt ratio is a low 12%.

Sporting hero

JD Sports Fashion has a P/E of 28, so not as high as the previous two. Its dividend yield is a very low 0.22% but it has a dividend cover of 15 times, which means it could increase if the company continues to thrive. Earnings per share are 26p.

It’s important to note that these stocks are currently overvalued, so I think they’re worth watching for the possibility to buy on a dip, but I wouldn’t rush out and buy them at today’s prices.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 ridiculously cheap shares to consider buying now

Harvey Jones can see plenty of cheap shares on the FTSE 100 and says the Iran conflict isn't the main…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

£1,000 buys 1,712 shares in this red hot defence-related penny stock that’s tipped to soar 75%

Edward Sheldon has just spotted a penny stock that appears to offer the winning combination of growth, value, and share…

Read more »

Aston Martin DBX - rear pic of trunk
Investing Articles

£7,500 invested in Aston Martin shares 5 weeks ago is now worth…

With Aston Martin shares down 66% in 13 months and now trading for just 40p each, should I buy the…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

With a P/E ratio of 11, could buying this stock be like investing in Meta Platforms in 2022?

I think Adobe shares today look a lot like Meta stock in October 2022. Could this be another chance for…

Read more »

Investing Articles

Should I wait for the point of maximum panic to buy UK shares?

Harvey Jones is keen to buy cheap UK shares for his Self-Invested Personal Pension. But should he jump in now…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Dividend Shares

The dividend yield of these 2 income stocks just jumped almost 25%

Jon Smith points out an income stock he feels is attractive given the recent share price slump, but also outlines…

Read more »

Rolls-Royce Hydrogen Test Rig at Loughborough University
Investing Articles

As Rolls-Royce buys its own shares, should I buy more too?

Buying Rolls-Royce shares has been one of James Beard’s best decisions. But is it possible to have too much of…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing For Beginners

Down 43% in a month, what on earth’s going on with the Vistry share price?

Jon Smith points out why the Vistry share price is enduring a tough period, and provides his outlook for the…

Read more »